WebSep 5, 2024 · Mild liver impairment (Child-Pugh A): 1.1 mg/m2 intravenously over 2 to 5 minutes on days 1 and 8 of a 21-day cycle Moderate liver impairment (Child-Pugh B): 0.7 mg/m2 intravenously over 2 to 5 minutes on days 1 and 8 of a 21-day cycle Severe liver impairment (Child-Pugh C): Data not available Dose Adjustments PLEASE NOTE: Web1 INDICATIONS AND USAGE . HALAVEN is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic diseasePrior therapy . should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.
$0 Co-Pay Program & Patient Assistance HALAVEN® …
WebDosage/Direction for Use. 1.4 mg/m 2 IV over 2-5 min on days 1 & 8 of every 21-day cycle. Patient w/ mild hepatic impairment (Child-Pugh A) 1.1 mg/m 2 IV over 2-5 min on days 1 & 8 of a 21-day cycle. Moderate hepatic impairment (Child-Pugh B) 0.7 mg/m 2 IV over 2-5 min on days 1 & 8 of a 21-day cycle. Click to view Halaven detailed prescribing ... WebAdults. 1.4 mg/m2 IV over 2 to 5 minutes on days 1 and 8; treatment cycles are repeated every 21 days until disease progression. Do not administer eribulin on day 1 or day 8 if the absolute neutrophil count is less than 1,000 cells/mm3, the platelet count is less than 75,000 cells/mm3, or a patient has a grade 3 or 4 non-hematological toxicity. fargefestival india
Patient Support - HALAVEN (eribulin mesylate) Reimbursement for ...
WebSep 22, 2024 · HALAVEN is indicated for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen [see Clinical Studies]. DOSAGE AND … WebHalaven ®. Eribulin is the generic name for the trade name drug Halaven. In some cases, health care professionals may use the trade name Halaven when referring to the generic drug name eribulin. Halaven is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. This medication is classified as a "non-taxane ... WebIndications/Uses Locally advanced or metastatic breast cancer who have progressed after at least 2 chemotherapeutic regimen for advanced disease. Locally advanced or metastatic HER2 -ve breast cancer after failure of 1 chemotherapeutic regimen for advanced disease. farge bryn trondheim